Connecticut 2013 Regular Session

Connecticut House Bill HB05460

Introduced
1/22/13  
Refer
1/22/13  
Refer
3/7/13  
Report Pass
3/19/13  
Refer
4/1/13  
Refer
4/1/13  
Report Pass
4/8/13  

Caption

An Act Establishing A Plan For Emerging Bioscience And Pharmaceutical Businesses In Southeastern Connecticut.

Impact

The implementation of HB 5460 could significantly affect state laws by emphasizing growth strategies tailored to the bioscience sector. If enacted, this bill could lead to improved economic conditions by attracting investments and developing workforce training initiatives related to the bioscience field. The targeted incentives could allow for more significant state engagement in providing tailored support for these specific industries, promoting a localized strategy for economic development in southeastern Connecticut and beyond.

Summary

House Bill 5460 aims to establish a strategic plan for fostering the growth of emerging bioscience and pharmaceutical businesses in southeastern Connecticut. The bill mandates the Commissioner of Economic and Community Development to develop this plan, which includes various initiatives such as targeted incentives for businesses, support resources for business formation, mechanisms to adapt to market changes, and integration with existing regional assets. This initiative is a response to the growing demand for biomedical innovations and aims to position Connecticut as a leader in bioscience industries.

Sentiment

Discussions surrounding the bill have generally been positive, with many stakeholders recognizing the potential for job creation and economic revitalization in southeastern Connecticut. Supporters argue that enabling a focused approach to bioscience and pharmaceutical growth aligns with national trends and demands in healthcare and biotechnology. However, there may be concerns regarding the adequacy of funding and resources to ensure the plan's successful execution, which will need to be addressed to maintain broad support.

Contention

Notable points of contention revolve around the potential allocation of state resources towards the bioscience industry versus other critical sectors. Some critics may argue that prioritizing one industry could lead to systemic imbalances and neglect of broader economic needs in the region. Additionally, the effectiveness of the proposed incentives and support mechanisms will need close scrutiny to ensure they meet the evolving needs of the bioscience sector and achieve the desired economic growth.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.